Can the company add a Car-T string to its stem cell transplant bow?
ApexOnco Front Page
Recent articles
AstraZeneca and GSK/iTeos's odysseys get a little lonelier still.
The company has caught up with Syndax and overtaken Kura in the first-line menin inhibitor race.
Could a new ADC project distract attention away from evorpacept?
A hit on EFS will challenge regulators, and points to Merck's design blunder in Keynote-585.
The German group has posted a PFS win in phase 3, but overall survival was confounded by crossover.
Merck & Co gives up on Agenus, while Sanofi hands BND-22 back to Biond.
The quiet acquisition of dordaviprone prompts a louder takeout by Jazz.
